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Abstract The clinical development of selective alpha-7
nicotinic acetylcholine receptor (a7 nAChR) agonists has
hitherto been focused on disorders characterized by cog-
nitive deficits (e.g., Alzheimer’s disease, schizophrenia).
However, a7 nAChRs are also widely expressed by cells of
the immune system and by cells with a secondary role in
pathogen defense. Activation of a7 nAChRs leads to an
anti-inflammatory effect. Since sterile inflammation is a
frequently observed phenomenon in both psychiatric dis-
orders (e.g., schizophrenia, melancholic and bipolar
depression) and neurological disorders (e.g., Alzheimer’s
disease, Parkinson’s disease, and multiple sclerosis), a7
nAChR agonists might show beneficial effects in these
central nervous system disorders. In the current review, we
summarize information on receptor expression, the intra-
cellular signaling pathways they modulate and reasons for
receptor dysfunction. Information from tobacco smoking,
vagus nerve stimulation, and cholinesterase inhibition is
used to evaluate the therapeutic potential of selective a7
nAChR agonists in these inflammation-related disorders.
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Introduction
Alpha-7 nicotinic acetylcholine receptors (a7 nAChRs) are
expressed in the central nervous system (CNS) and are
thought to play a role in a wide variety of psychiatric and
neurological disorders. Peripheral and CNS immune cells
strongly express a7 nAChRs; activation of a7 nAChRs on
these cells has been shown to suppress inflammatory pro-
cesses. Since inflammation is involved in several
psychiatric disorders, as well as in basically all neurolog-
ical disorders, specific a7 nAChR agonists could display
therapeutic effects. In the current review, we summarize
information on receptor expression, the intracellular sig-
naling pathways modulated by these receptors, reasons for
receptor dysfunction, clinical evidence for altered a7
nAChRs, and we conclude with a discussion about poten-
tial indications for selective a7 nAChRs agonists.
Expression of a7 nAChR
Distinct from most nicotinic acetylcholine receptors
(nAChR), the a7-subtype mainly forms homomeric, rather
than heteromeric pentamers. In the central nervous system,
including the human brain, such nicotinic-a7 homomeric
pentamers are expressed by pyramidal and interneurons [1–
3]. Apart from neurons, immature (doublecortin positive)
granule cells [4], astrocytes [5–7], and microglia cells [8–
13] also express the a7 nAChR. Finally, NG2-positive cells
(these are oligodendrocyte precursors) also express a7
nAChRs [5, 14]. The dogma that a7 nAChRs exclusively
assemble as homomeric pentamers was recently overturned
by the discovery that a7 subunits also form heteromeric
pentameric ion channels with b2 subunits [15]. Such het-
eromeric a7b2 channels were found on cholinergic
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projection neurons in mouse and human basal forebrain
[15, 16]. Concerning function, activation of a7 nAChRs
results in strong calcium and sodium influxes, which in the
case of a presynaptic location facilitates neurotransmitter
release [17, 18]. A postsynaptic localization on parvalbu-
min-positive GABA neurons suggests a role in
synchronized oscillatory output of pyramidal neurons.
Outside the brain, the receptor is expressed on several
cell types of the immune system. This includes monocytes
[19–21], dendritic cells [22], macrophages [23–26], T-cells
[27, 28], and B-cells [29, 30]. The receptor has also been
identified on additional cell types known to play a role in
the host’s defense against pathogenic organisms. Examples
are the microvascular endothelium [31], keratinocytes [32,
33], placenta [34], bronchial epithelial cells [35], platelets
[36], adipocytes [37], and synoviocytes [38]. During
wound healing, expression of a7 nAChRs is transiently
observed on fibrocytes and myofibroblasts in the wound
zones [39]. Completing this list, a7 nAChRs were detected
in mouse testes, in mouse and human sperm (where they
modify sperm motility [40]), in rat superior cervical gan-
glia [41], and in group-IV muscle afferent neurons [42].
Not unexpectedly, numerous cell lines endogenously
express a7 nAChR too. This includes rat PC12-cells [43],
human SH-SY5Y neuroblastoma cells [44, 45], mouse
RAW264.7 [46, 47], the human leukemic T-cell line
MOLT3 [48], the human monocyte U937 cell line [20, 49],
and immortalized human T-lymphocyte ‘Jurkat’ cells [27].
Recombinant expression has also been achieved in cell
lines that endogenously express the chaperones required for
a7 nAChR expression, e.g., SH-EP1 cells [50], SH-SY5Y
[51], or GH3 cells [52].
With respect to the above-listed localizations of a7
nAChR, a word of caution is needed, since some expres-
sion studies are confounded by the use of tools that also
detect a distinct, duplicated a7-like protein ‘dupa7’ [26,
53], by the use of antibodies which recognize cross-react-
ing epitopes [54] or by the use of the non-selective
radioligand MLA (besides a7 nAChRs this compound also
binds to nicotinic a3/a6b2b3* receptors, see [55]).
In addition to expression on the cell surface, an intra-
cellular localization of a7 nAChRs has been observed in
brain mitochondria [56]. In this organelle, the a7 nAChR
may assemble with b2 subunits where it presumably
influences pore formation and cytochrome-c release [57].
Intracellular signaling pathways
In mouse hippocampal neurons, a7 nAChRs are charac-
terized by rapid activation and desensitization. The
fractional calcium current (Pf) has been assessed and found
to be 6.1 [58]. This indicates that in neurons a7 nAChRs
have a special role in the modulation of intracellular cal-
cium, enabling substantial calcium entry at resting or
hyperpolarized membrane potential, which is different
compared to other nAChRs, but similar to NMDA recep-
tors at depolarized membrane potential. However, thus far,
it is not known if this also holds true for a7 nAChRs in
other cells (e.g., immune cells). The intracellular pathways
following a7 nAChR activation in non-neuronal cells
involve calcium influx through the channel pore, which
then triggers calcium-induced calcium release from ryan-
odine- and IP3-dependent stores [10, 28, 59]. Further long-
lasting intracellular pathways involve activation of intra-
cellular phosphatases and kinases, which trigger signaling
events independent of an ion flux (which implies that the
a7 nAChR acts as metabotropic receptor) [60]. For
instance, activation of a7 nAChRs leads to stimulation of
adenylate cyclase-1 and thus to increases in cAMP levels
[61]. This in turn stimulates protein kinase A (PKA), which
may result in further signaling events such as CREB acti-
vation [61] and GSK3 inhibition [62]. Activation of the a7
nAChR on non-neuronal cells inhibited TLR3-, TLR4- or
TLR9-induced transcription and release of inflammatory
cytokines [9, 19, 21, 34, 47]. One of the intracellular sig-
naling cascades described in this context is a pathway that
involves JAK2-mediated tyrosine-phosphorylation of the
p85 subunit of PI3 K, activation of Akt and CREB, and
subsequent inhibition of (or competition with) NFjB [20,
25, 49, 63] (see Fig. 1). Egea and colleagues emphasize
that this pathway furthermore leads to activation of the
transcription factor Nrf2, which is important for tran-
scription of numerous anti-oxidative proteins and for the
induction of an anti-inflammatory phenotype of microglia
cells [64]. Alternatively, downstream signaling towards
NFjB may involve JAK2 activation of STAT3 [65–68]
(see Fig. 1). Finally, activation of a7 nAChRs can result in
inhibition of p38 MAP-kinase [8, 10, 19]. A functional
consequence of this latter pathway is inhibition of the re-
lease of inflammatory mediators like TNFa and HMGB1
[8, 10, 19].
The anti-inflammatory activity of a7 nAChR
stimulation
As early as 1998, Sugano et al. [49] described that nicotine
displayed an anti-inflammatory activity involving inhibi-
tion of NFjB-signaling. Following this observation, it was
shown that the receptor responsible for this response was
the a7 nAChR subtype [20, 23, 24, 69, 70]. Moreover, it
was shown that the anti-inflammatory effect of electrical
stimulation of the vagus nerve was also mediated by the a7
nAChR [23, 24, 69]. Notably, after splenectomy the ben-
eficial effects of vagus nerve stimulation were lost [71], but
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some controversy still exists about the exact localization of
the a7 nAChRs involved in the response to vagus nerve
stimulation. The vagus nerve is supposed to activate the
celiac ganglion, which is the origin of the adrenergic
splenic nerve. According to one scenario, the splenic nerve
releases noradrenaline onto memory T-cells (CD4?
CD44high, CD62Llow), resulting in synthesis and release of
acetylcholine that activates a7 nAChRs on spleen-macro-
phages [69, 72, 73]. The alternative proposal assumes that
the a7 nAChRs are localized postsynaptically in the celiac
ganglion. This view is supported by data showing that
postganglionic stimulation of the splenic nerve still results
in an anti-inflammatory response, even in mice with a
genetic deletion of the a7 nAChR [74]. However, in a
critical review Martelli [75] proposes that efferent vagus
nerve stimulation achieves its anti-inflammatory effect via
a non-neuronal (humoral) pathway. It is evident that this is
an area that is still very much in development. Interest-
ingly, activation of glucocorticoid receptors increases the
expression of a7 nAChRs [76]. This implies that the anti-
inflammatory activity of glucocorticoids may include a
nicotinergic mechanism. Overall, given the expression
pattern, the cellular signaling cascades, and information
from vagus nerve stimulation, the data strongly indicate
that activation of the a7 nAChR suppresses the respon-
siveness of the immune system.
Surprisingly, whereas the activity of positive allosteric
modulators (PAMs) in animal models of learning/memory
or on evoked potentials is well documented (see [77] for a
recent review), there is a paucity of reports on their anti-
inflammatory activity. In this context, PNU-120596 has
been shown to attenuate TNFa and IL-6 in a rodent model
of inflammatory pain. These findings have been recently
corroborated with a different molecule (‘‘PAM-2,’’ [78]).
Along the same lines several reports have shown that a7
nAChR PAMs reduce brain injury and improve neurolog-
ical function after focal cerebral ischemia in rats [79–81].
Notably, the anti-inflammatory response to a7 nAChR
stimulation also occurs in the brain. Thus, activation of a7
nAChRs is known to alter the phenotype of both macro-
phages and microglia from an M1-like to an M2-like
phenotype [11, 19, 82, 83]. Consequently, any dysfunction
in the a7 nAChR and its signaling processes could tip the
balance towards more inflammation.
Reasons for dysfunction of the a7 nAChR
Dysfunction of a7 nAChRs may have a variety of causes.
For adequate membrane insertion, the a7 nAChR has to be
assembled first as a pentamer and is thereafter shuttled to
the plasma membrane. This process requires several
chaperone molecules such as RIC3, SLURP1, Lynx1,
EPHB2, or PICK1, and evidently, their dysfunction could
affect receptor level and function [1, 33, 48, 84–88]. In
addition, transcription of the a7 nAChR can be diminished
by heterozygotic or homozygotic 15q13.3 microdeletions
[89], by methylation of the promotor [90] or by MeCP2
(methyl CpG binding protein 2) dysfunction [91].
Moreover, activity of the a7 nAChR is modified by
phosphorylation. An as yet undefined tyrosine-phosphory-
lated protein was shown to inhibit the functional activity of
the a7 nAChR, whereas tyrosine kinase inhibition by
genistein enhanced surface expression of the a7 nAChR
[35, 37, 84, 92] or its function [51]. Serine-phosphorylation
of the a7 nAChR can influence function too. It has been
reported that activation of D1/D5 dopamine receptors
attenuated a7 nAChR currents via PKA-mediated phos-
phorylation of the serine residue 365 in the M3–M4
cytoplasmic loop of the channel [93]. Other possibilities
have been proposed as well. For instance, diminished sig-
naling of a7 nAChR might result from increased levels of
the purported endogenous a7 nAChR inhibitor, kynurenic
acid [94], though conflicting data have been reported too








































Fig. 1 Schematic anti-inflammatory signaling pathways activated by
nAChR a7. Stimulation of nAChR a7 activates Jak2 leading to
inhibition of NFjB and GSK3 but also to CREB activation. A
separate signaling cascade involves activation of PKA and AKT
enabling the nuclear translocation of Nrf2 (NFE2L2), which drives
expression of HMOX1 (HO-1). This pathway elicits potent anti-
inflammatory and neuroprotective effects
Modulatory effects of a7 nAChRs on the immune system and its relevance for CNS disorders 2513
123
the signaling pathway downstream of the receptor may be
altered [27, 66, 92]. Furthermore, dysfunction of the a7
nAChR could result from the presence of the CHRFAM7-
gene. This gene encodes a dominant negative variant of the
a7 nAChR [26, 96] and is unique for humans [26, 97].
Transcripts, often described as ‘dupa7’, have been found in
the promyelocytic leukemia cell line HL-60 [26], mono-
cyte cell lines (THP1, U937, and Mono-Mac6 [98]), and
neuroblastoma cell lines (SH-SY5Y, IMR32 [98]). High
levels of dupa7 transcripts have also been described in
native immune cells such as peripheral blood monocytic
cells, lymphocytes and synoviocytes, and in lower amounts
also in human brain tissue [7, 26, 53].
Rapid metabolism of acetylcholine and receptor
desensitization
Cholinergic innervation in the brain arises mainly from two
sources. Cholinergic neurons from the medial septal
nucleus innervate the hippocampus [99], whereas cholin-
ergic nerves from the basal forebrain (including the nucleus
basalis Meynert) project to the cortex, amygdala, caudate
nucleus, putamen, and thalamus [100]. Acetylcholine
locally released by cholinergic neurons is assumed to cross
the synaptic cleft despite effective catabolism by choli-
nesterases [101]. However, it is less clear whether volume
transmission to extrasynaptic neuronal sites is sufficiently
high to lead to relevant a7 nAChR stimulation. Outside the
brain, high levels of cholinesterases are found in the blood
and therefore it has been questioned whether a7 nAChRs
on, for example, circulating immune cells will be exposed
to levels of acetylcholine that are sufficient for activation
[102]. Further doubts about the physiological relevance of
a7 nAChRs relate to their rapid desensitization [101, 103,
104]. However in the latter case, there are two counter-
arguments. In the first place, a7 nAChRs not only rapidly
desensitize, they also quickly recover [105]. The second
argument is that intracellular effects are presumably more
sustained and therefore could outlast receptor desensitiza-
tion. Vijayaraghavan et al. [6] provide yet one more piece
of information, which, in addition, addresses the issue of
volume transmission. The authors found that extracellular
levels of choline-acetyl transferase (ChAT) are actively
regulated. This means that, despite ongoing extracellular
cholinesterase-activity, extracellular acetylcholine is per-
manently resynthesized. As a consequence, acetylcholine
may act over long distances from its site of release.
Importantly, acetylcholine is not only synthesized and
released by neurons but also by several non-neural cells.
Frequently these cells express both ChAT and a7 nAChRs,
and as a result, an intrinsic paracrine loop is formed [102].
Examples are bronchial epithelial cells [35], lymphocytes
[6, 28], human neuronal stem cells [6], and astrocytes [6,
106]. As a last argument in favor of a physiological rele-
vance of extrasynaptic a7 nAChRs, it should be mentioned
that these receptors are also activated by choline, the pre-
cursor and hydrolytic split product of acetylcholine [46, 67,
81, 107]. In summary, extrasynaptic a7 nAChRs will be
readily activated under physiological conditions.
Diseases in which treatment with a7 nAChR
agonists could be useful
Since a7 nAChRs are expressed on interneurons, presy-
naptically on glutamatergic neurons, and on neuronal
progenitor cells, the logical prediction was that a7 nAChR
agonists could provide a beneficial influence on cognitive
function. Consequently, the clinical testing of a7 nAChR
agonists has focused on disorders with profound cognitive
dysfunction (i.e., schizophrenia, Alzheimer’s disease). The
fact that nicotinic a7 receptors are also strongly expressed
by cells of the immune system, including those of the brain
innate immune system, has often been (but not always, [64,
108]) overlooked. With this in mind, in the following
sections we will reflect on the therapeutic use of selective
a7 nAChR agonists in psychiatric and neurological
disorders.
Depression
Inflammation and exposure to stress are generally recog-
nized as strong proximal factors for the development of
depression symptoms [109]. Many kinds of stress, but in
particular those involving threat, loss, entrapment, and
humiliation, lead to activation of the immune system [109–
112]. This has been conceptualized as an anticipatory
response by the innate immune system to prepare for
physical injury [113]. Phagocytic cells such as macro-
phages and microglia are essential components of the
innate immune system and contribute to the host’s defense
against invading microorganisms. Notably, phagocytes
from patients with depression are hyper-responsive [114–
116]. Upon activation, these cells produce cytotoxic com-
pounds like nitric oxide and oxygen radicals [117, 118].
These reactive oxygen radicals formed during the ‘respi-
ratory burst’ may irreversibly oxidize tetrahydrobiopterin
[119]. Since tetrahydrobiopterin is an essential cofactor for
the production of dopamine, noradrenaline, and serotonin,
the heightened activity of microglial cells may ultimately
lead to a reduction in central monoamine levels (see
Fig. 2). This could be the underlying cause of low mood
and anhedonia in depression (Kalkman and Feuerbach, in
preparation). As outlined above, a7 nAChRs are expressed
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both on macrophages and microglia, and their activation
leads to anti-inflammatory effects. In particular, activation
of a7 nAChRs might lead to a shift in microglia phenotype
from M1-like (activated for anti-microbial activity) to M2-
like (resolution, removal of debris) [10, 11, 13, 83, 120],
while a similar process has been described in the periphery.
Stimulation of a7 nAChRs attenuates macrophage
responsiveness and diminishes release of cytokines [23, 46,
47, 66] and therefore will limit the negative impact of
inflammation on tetrahydrobiopterin metabolism.
Activation of a7 nAChRs in the brain has been shown to
activate protein kinase A (PKA) via a mechanism involv-
ing calcium-dependent activation of adenylatecyclase-1
and, consequently, an increase in cAMP levels [61]. PKA
is one of the kinases that increase Ser9-phosphorylation of
GKS3b, which results in inhibition of the kinase activity.
PKA also fosters Ser133-phosphorylation of the transcrip-
tion factor CREB. Ser133-P-CREB is a substrate for
GSK3b, which subsequently results in rapid catabolism of
CREB and thus termination of CREB signaling. CREB
competes with NFjB for binding to CREB-binding protein
(CBP), and therefore limits the inflammatory NFjB signal.
Activation of a7 nAChRs in the brain may thus lead to an
anti-inflammatory activity. Increased PKA activity,
increased Ser9-phosphorylation of GSK3b, and increased
Ser133-phosphorylation of CREB have all been observed
in mouse brain after chronic treatment with the a7 nAChR
agonist A582941 [62]. Notably, Ser9-phosphorylation of
GSK3b following A582941 treatment was absent in mice
with a genetic deletion of the a7 nAChR [121].
Vagus nerve stimulation, which reduces inflammation
[23, 66, 69, 122], has been approved for treatment of drug-
resistant depression in humans [123]. In long-term natu-
ralistic studies, significant improvements and increasing
remission rates were noted in patients with refractory
depression [124–126]. Oxytocin (reported to display
antidepressant activity [127]) increases the excitability of
central vagal neurons in rats [128] and inhibits LPS-in-
duced release of inflammatory cytokines in healthy human
subjects [129]. The antidepressant activity of oxytocin
could thus be a consequence of stimulation of the cholin-
ergic anti-inflammatory pathway. In conclusion, there is
accumulating evidence that a7 nAChR agonists could
possess antidepressant activity, although none of the
compounds that were in clinical development has been
tested in this indication.
Schizophrenia
Symptoms of schizophrenia are commonly divided into
three domains, namely positive symptoms (delusions, hal-
lucinations), negative symptoms (social withdrawal,
anhedonia), and cognitive deficits (learning and memory
deficits, alogia). A history of maternal and prenatal infec-
tions, prior hospitalization for severe infection, and
autoimmune comorbidity represent major risk factors for
schizophrenia [130]. These conditions, which are linked to
the elevation of pro-inflammatory cytokines has led to the






























Fig. 2 Microglia cells play a role in eradication of invading
microorganisms and in removal of debris. During these processes,
the cells adapt specialized phenotypes (M1 and M2-like, respec-
tively). During the respiratory burst, labile oxygen products are
formed that oxidize microbial proteins and nucleic acids, but also
oxidize the essential cofactor for monoamine synthesis, tetrahydro-
biopterin. Sterile neuroinflammation is a common observation in
neurological and psychiatric disorders. Acetylcholine, acting via a7
nAChRs, promotes M2-polarization. As such, it reduces neuroin-
flammation, while promoting phagocytosis. M2-polarized microglia
cells not only produce neurotrophins and anti-inflammatory cytoki-
nes, they also effectively phagocytose and catabolize Ab. a7 nAChR
agonists are expected to improve neurological and psychiatric
disorders via inhibition of neuroinflammation, to restore tetrahydro-
biopterin levels (improve mood symptoms) and to provide
neuroprotection
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This hypothesis proposes that early alterations in the
peripheral and central innate immune system disrupt nor-
mal development and maturation of neuronal systems
during the juvenile and early adult stages of life, affecting
processes such as myelination, synaptic pruning, and neu-
ronal modeling [131]. Results from genetic studies are
consistent with such a process, as confirmed genetic risk
factors for schizophrenia include mutations in genes
involved in immune function (e.g., HLA-C and HLA-
DRA) and synaptic pruning [132, 133]. The first episode of
psychosis is often associated with microglia activation
[130, 134, 135], elevated levels of pro-inflammatory
cytokines in the CSF [136–138], and a significant loss in
white matter volume (reviewed in [136]). It is assumed that
cytokines, chemokines, prostaglandins, and reactive oxy-
gen products released by activated microglia generate a
toxic milieu for oligodendrocytes (leading to white matter
loss) and neurites (gray matter loss) [130, 136, 139, 140].
The severity of negative symptoms correlates with the
diminution of white matter [130].
The impetus to develop a7 nAChR agonists was based
on two sets of clinical information. First, the early literature
reported extremely high values for the prevalence of
smoking in schizophrenia patients (see [141]). This infor-
mation was supplemented by data from radioligand binding
experiments investigating brain tissue of deceased
schizophrenia patients (for summary see [100]). Using
[125I]-a-bungarotoxin (a-btx) as radioligand, a reduction in
labeling of the a7 nAChR was found in the dentate gyrus
[142], the reticular nucleus of the thalamus [143], the
frontal cortex [144], and the cingulate cortex [1]. A vast
body of genetic literature supports the contention that the
functionality of the a7 nAChR in schizophrenia is dimin-
ished. CHRNA7, the gene encoding the a7 nAChR, is
located on 15q14, a chromosomal area that is linked to
genetic transmission of schizophrenia [145]. This area is
also subject to deletion copy number variations (CNVs,)
[146, 147]. Decreases in a-btx binding observed in
schizophrenia patients could be due to an increased
expression and insertion of dupa7, since heteromeric
dupa7/a7 nAChRs do not bind this radioligand [84, 148].
Notably, decreased a-btx binding is unlikely to be
explained by differences in smoking behavior [1]. Poly-
morphisms in the CHRNA7 promoter that decrease gene-
transcription are also associated with schizophrenia [149].
A 2 bp deletion allele in CHRFAM7A is frequent in
Caucasians (42 %) and less in African-Americans (14 %)
[150]. This 2 bp deletion form of CHRFAM7A is an even
stronger inhibitor of a7 nAChR than wild-type
CHRFAM7A and consistent with this, several studies
support an association of the 2 bp deletion in the
CHRFAM7A gene with schizophrenia and bipolar disorder
(summarized by Sinkus et al. [150]). Finally, CNVs occur
in the CHRNA7 and in CHRFAM7A, and deletions were
strongly associated with schizophrenia. Interestingly, this
was especially the case when the CHRNA7 was deleted,
while CHRFAM7A was present [150].
The pathophysiological consequence of the diminished
functionality was mainly sought in the cognitive domain.
The prediction that a7 nAChR agonists would improve
cognition in schizophrenia was tested clinically with a
series of development compounds (for a recent reviews, see
[100, 151, 152]). Since the nicotine a7 receptor and the
5HT3 receptor are phylogenetically very similar, several
developmental a7 nAChR agonists lack selectivity and
block the 5HT3 receptor concomitantly [108]. Encenicline
(EVP6124), which is a mixed a7 nAChR agonist/5HT3
antagonist, showed significant clinical improvement on
PANSS cognitive impairment domain and also for the
PANSS negative scale [153]. Another mixed a7 nAChR
agonist and 5HT3 antagonist tropisetron significantly
reduced PANSS total and the negative symptom subscale
with increasing treatment time [154]. Further, a mixed a7
agonist/5HT3 antagonist RG3487 (also known as
MEM3454), was reported to improve negative symptoms
and depression ratings [155]. It remains unclear if the
beneficial effect on negative symptom ratings is due to a7
nAChR activation or to 5HT3 blockade, as both a selective
a7 nAChR agonist (TC-5619) and a selective 5HT3
antagonist (ondansetron) improved negative symptoms
[156, 157]. DMXB-A (GTS-21) [158], a a7 nAChR agonist
with additional inhibitory activity at a4b2 nAChRs [159],
improved alogia and anhedonia ratings in the scale for
assessment of negative symptoms. Remarkably, a7
nAChR-positive allosteric modulators (galantamine,
galantamine plus choline, and JNJ39393406) were com-
pletely inactive [100]. Taken together, these data show that
a7 nAChR activation did not improve positive symptoms,
whereas a beneficial effect against negative symptoms was
observed repeatedly. The clinical evidence that a7 nAChR
activation leads to improvement of cognitive dysfunction
in schizophrenia still remains somewhat equivocal [100,
160], although the data for encenicline are encouraging
[153, 161]. It is noteworthy that the clinical development of
several mixed nAChR a7 agonist/5HT3 antagonist com-
pounds (e.g., RG3487, tropisetron) in schizophrenia has
been halted [152]. This may be related to side effects
associated with 5HT3 receptor blockade (e.g., constipation,
arrhythmias) (see [108, 162, 163]). Currently, three a7
nAChR agonists remain in clinical development
(AQW051, encenicline, and GTS-21) [152].
The observation that nAChR a7 agonists improve neg-
ative symptoms is remarkable. It can be speculated that
stimulation of nAChRs a7 counteracts microglia activa-
tion, such that white and gray matters are exposed less to
the toxic microglia products. In this respect it is noteworthy
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that minocycline, a compound which suppresses microglia
activation, also specifically improved negative symptoms
(for review see [164]). Negative symptoms, like symptoms
of melancholic depression, might reflect distinct behavioral
consequences of central inflammation. However, it could
be that negative symptoms are not distinct and in fact
reflect aspects of melancholic depression, or that rating
scales for negative symptoms do not discriminate between
depression symptoms and negative symptoms [155]. Since
microglia activation occurs early in the disease process
(i.e., during, or even before, the first period of psychosis),
early intervention with compounds that limit microglia
activation (nAChR a7 agonists, minocycline) might be
appropriate.
Bipolar disorder
The cardinal features of bipolar disorder are recurrent
episodes of depression and hypomania, whereas the latter
includes euphoric or irritable mood, mental and behavioral
over-activity, as well as decreased need for sleep and
involvement in risky activities [165]. As for major
depressive disorder, diseases and habits that are associated
with peripheral inflammation (diabetes, obesity, cardio-
vascular disease, smoking, and alcohol abuse) are
recognized risk factors for bipolar disorder (reviewed in
[166–168]). And in further similarity to major depression,
childhood trauma is a strong predictor for appearance of
bipolar disorder later in life [169]. Increases in serum
levels of inflammation markers have been observed during
manic, depressed and even euthymic phases [170–173].
Bipolar disorder shares genetic risk loci with schizophrenia
and with major depression [171, 174]. There is evidence
for microglia activation in the brain of bipolar disorder
patients: first, higher levels of IL1b, IL1R, MYD88, and
iNOS have been found in a post-mortem study in the
frontal cortex [175]. Second, microglia-derived inflamma-
tion markers MCP1 and YKL40 were increased in CSF
[176], and third, microglia activation was detected by
PK11195 imaging [177]. The inflammatory milieu in the
brain is probably responsible for atrophy, volumetric
changes, cognitive decline, and symptom worsening [167,
175]. The same genetic polymorphisms, copy number
variations and alteration in the pseudo-gene CHRFAM7A,
which are presumed to diminish the functionality of the
nAChR a7 receptor in schizophrenia, have also been
detected in bipolar disorder [161, 178].
The neurodevelopmental consequences of diminished
a7 nAChR signaling may be inferred from studying
CHRNA7 knockout mice. It has been reported that nicotine
administration to these animals led to a longer period of
elevated extracellular dopamine levels in the nucleus
accumbens than in control mice [179]. Excessive dopamine
signaling via D2 receptors in the striatum causes an acti-
vation of GSK3b via a multiprotein complex involving the
D2 receptor, b-arrestin, Akt, GSK3b, and PP2A [180, 181],
while active GSK3b results in diminished long-term
potentiation (LTP) [182–184]. Unexpected rewarding out-
comes result in dopamine release in the striatum, whereas
unpredicted negative outcomes result in a strong reduction
in dopamine output [185]. Such a dopamine ‘‘dip’’
improves avoidance learning (via D2 receptor hypo-stim-
ulation) by decreasing GSK3b activity, and thus promoting
LTP. In contrast, hyper-stimulation of D2 receptors, and
activation of GSK3b, both result in a diminished learning
from incorrect reward predictions. If we assume that the
a7-p85-Akt-GSK3b pathway is activated in striatal neu-
rons (as it is in immune cells), dysfunction of the a7
nAChR would result in reduced inhibitory GSK3b-phos-
phorylation, in poorer learning from unrewarding
conditions, and eventually in more (i.e., less suppressed)
risk-taking behavior. Taken together, dysfunction of the a7
nAChR would increase both depression-risk and hypoma-
nia symptoms. The prediction that selective a7 nAChR
agonists might counteract these symptoms remains to be
tested.
Autism spectrum disorder
Autism is a general term for a group of neurodevelop-
mental disorders characterized by difficulties in social
interaction, verbal and non-verbal communication, and
repetitive behaviors. Several distinct subtypes have been
identified, and these are often combined under the umbrella
diagnosis ‘‘autism spectrum disorder’’ (ASD). Certain
genetic copy number variations, which can be either
inherited or occur de novo, exert a profound effect on brain
development and lead to syndromes that fit the ASD
diagnosis. The 15q13.3 microdeletion syndrome is such an
example. Gillentine and Schaaf [147] collected all pub-
lished cases of heterozygous 15q13.3 deletions and
calculated that nearly half of them displayed cognitive
deficits, while seizures and symptoms of ASD were noted
in 26 and 21 % of these cases, respectively. It is not clar-
ified by which mechanism heterozygosity for the a7
nAChR could lead to ASD. It is known, however, that the
a7 nAChR is essential for the formation of NMDA
synapses [86], and that the absence of functional a7
nAChRs results in perturbation of NMDA neurotransmis-
sion at glutamatergic synapses [186]. The EphB2 receptor
is involved in the process by which a7 nAChRs enhance
formation of NMDA synapses [86, 187] and, interestingly,
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also dysfunction of the EphB2-receptor has been recog-
nized as a risk factor for autism spectrum disorder [188].
Rett syndrome is another distinct genetic form of aut-
ism. In the majority of cases, Rett syndrome is caused by a
mutation in the MeCP2 gene; the functional consequence
of this mutation is a severe reduction in the expression of
a7 nAChRs [91]. Yasui and colleagues have therefore
proposed to use a7 nAChR agonists for the treatment of
Rett syndrome.
Although the pathology seen after partial deletion or
dysfunction of the a7 nAChR provides support for its
physiological role, it also creates a dilemma for pharma-
cotherapy with a7 agonists. Such compounds can only
work when the receptor is present and functional. A study
by Le Pichon and colleagues exemplifies this [189]. The
authors created lymphoblastoid cell lines from a patient
with a homozygous 15q13.3 microdeletion, his heterozy-
gous parents, and from several further family members and
age-matched controls. The lymphoblast cells were treated
with lipopolysaccharide, which provoked the expected
increase in TNFa release. TNFa release was suppressed by
nicotine (which in turn could be blocked by the a7 nAChR
antagonist a-btx) in all control and hemizygous deletion
cell lines, but notably not in lymphoblasts from the index
patient [189]. Patients with a strongly dysfunctional or
absent a7 nAChR will not benefit from a a7 nAChRs
agonist. It is reasonable to assume that cases of moderate
hypoactivity of the a7 nAChR will exist among the wide
spectrum of autism disorders, but the challenge will be to
identify a biomarker to enable their selection. The current
clinical evidence for a therapeutic effect of an increase in
cholinergic signaling in ASD is quite limited. It is based on
a few open label studies, case reports and a single small-
size double-blind augmentation study with a cholinester-
ase-inhibitor [190].
In a subset of autism patients, there is evidence for an
increase in allergic inflammation [191] and for mast cell
activation [192]. These observations hint to an increased
TH2 polarization (perhaps owing to a helminth infection).
An infection with a helminth would skew the differentia-
tion of helper T-cell towards the TH2 phenotype. IL4 and
IL5, cytokines produced by TH2 cells [193], promote
macrophage/microglia M2A polarization and mast cell
activation [194–196]. Indeed, Gupta et al. [197], recently
reported that the expression pattern of microglia genes in
autism cases was characteristic for an increased M2A
phenotype. Treatment with a7-agonists is expected to
further increase M2 polarization, and thus could accentuate
the autism-phenotype. According to this line of reasoning,
the treatment with a7 nAChR agonists might be contra-
indicated in at least some forms of autism spectrum
disorder.
Multiple sclerosis
Neuroinflammation represents a key aspect of the neuro-
logical disorders that will be discussed in this and
following sections. Multiple sclerosis (MS) is an autoim-
mune disease that affects axonal nerve transmission in
peripheral, lumbal, and central nerves, which as first
symptoms often results in motor and sensory problems.
Depression is a common comorbidity [198]. The precise
sequence of events that leads to MS in patients is not
known [199], but activation of lymphocytes, macrophages,
dendritic cells, and microglia are known to occur early in
the disease [200]. a7 nAChR activation can lead to inhi-
bition of lymphocyte proliferation [28, 201] and to
inhibition of macrophage and microglia activation [8, 11,
24, 25, 46]. Stimulation of a7 nAChR on endothelial cells
furthermore limits the extravasation of leukocytes during
inflammation [31], although it is not known if this is also
true for the blood–brain barrier. Together, these findings
suggest that a7 nAChR agonists might be therapeutically
useful in multiple sclerosis. Indeed, nicotine was shown to
inhibit experimental MS in rodents [83, 201], but to our
knowledge, selective a7 nAChR agonists remain to be
investigated in human MS.
Parkinson’s disease
The motor symptoms of Parkinson’s disease (PD) are
ascribed to degeneration of dopaminergic neurons in the
substantia nigra pars compacta. Other important symp-
toms are anxiety and depression, as well as memory loss,
confusion, and dementia. In this respect, it is noteworthy
that not only dopamine neurons perish but also the
cholinergic system. Degeneration of the basal forebrain
cholinergic system occurs early in the disease process and
precedes the dementia symptoms [202, 203]. In fact, in PD-
dementia the levels of cerebral ChAT are reduced to levels
below those seen in Alzheimer’s disease [204], whereas
cholinesterase inhibition improves dementia in Parkinson’s
disease [205].
A large number of epidemiological studies (for a recent
summary see [120]) have consistently shown that smoking
is associated with a lower incidence of PD. Data from
preclinical models of Parkinson’s disease indicate that
nicotine and selective a7 nAChR agonists reduce microglia
activation and neuroinflammation, and prevent nigro-stri-
atal dopamine-neuronal loss [206, 207]. a7 nAChRs
expressed on astrocytes may also contribute to the neuro-
protective effect, since activation of these receptors
suppressed astroglial apoptosis induced by oxidative stress
and preserved neurotrophic factor supply by glial cells
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[208]. An alternative suggestion is that nicotine reduces PD
symptoms owing to its stimulant effect on nigro-striatal
dopamine release. This nicotine-induced dopamine release
is mediated primarily via a6b2-containing receptors
localized on dopaminergic neurons. These neurons are
particularly vulnerable to damage and in models of nigro-
striatal damage, the a6b2-receptor numbers are signifi-
cantly reduced [209]. For this reason, it is rather unlikely
that the indirect dopamine release induced by nicotine
acting on a6b2 receptors plays a significant role in the
positive effect of smoking in PD. Post-mortem studies of
brains from patients with Parkinson’s disease provide
convincing evidence for neuroinflammation in the pars
compacta, with increases in neurotoxic cytokines, micro-
glia activation, and lymphocyte infiltration (reviewed by
Hirsch and Hunot [210]).
Depression occurs in about 35 % of PD-patients [211]
and might develop in the premotor stage of the disease
[211, 212]. Consistent with theories about microglia acti-
vation as contributor to depression [213, 214], depressive
symptoms may be considered as an early indicator of
Parkinson’s disease. The protective effect that smoking
exerts on PD could thus relate to a7 nAChR-mediated anti-
inflammatory activity of nicotine [11]. This would imply
that selective a7 nAChR agonists could be effective as
prophylactic treatment for Parkinson’s disease. In this
respect, it is worthwhile to mention that in MPTP-treated
laboratory animals, the density of a7 nAChR increases
(which is in contrast to a6b2-containing nAChRs, see
above) [215]. The a7 nAChR agonist AQW051 [216] has
been tested in patients with established Parkinson’s disease
(ClinicalTrials.gov), but results remain to be published.
Alzheimer’s disease
One of the functions of microglia is to remove debris [217].
Microglia cells phagocytose and subsequently degrade Ab,
and thereby promote the removal of Ab from the brain
[218]. As mentioned before, microglia cells assume dif-
ferent phenotypes. With aging, microglia shift their
morphology to a pro-inflammatory state and presumably
lose their ability to phagocytose [219]. Activation of a7
nAChR expressed on microglia alters the phenotype and
promotes phagocytosis and metabolism of Ab [12]. Based
on these data, one would expect that nicotine (smoking)
and cholinesterase inhibitors would diminish Ab load and
improve Alzheimer disease. In transgenic animals, over-
expressing Ab beneficial effects of nicotine or ChE-I were
indeed observed, while knock out of the a7 nAChR
worsened pathology [12, 62, 220]. In patients with Alz-
heimer’s disease, cholinesterase inhibitors limit the
cognitive deficits early in the course of the disease, but
dosing and efficacy are limited by cholinergic (in particular
muscarinic) side effects. For this reason, it is expected that
a7 nAChR agonists might reach a similar therapeutic
efficacy, but with less side effects. In a recent meta-anal-
ysis of prospective cohort studies investigating the effect of
smoking on dementia and Alzheimer’s disease, smoking
increased risk for dementia and AD [221]. This meta-
analysis study included 37 studies with a total of almost 1
million patients and the statistical power was sufficient to
investigate the influence of age. The increase in dementia
risk was observed in the age group between 65 and 75,
whereas the interpretation of results from patients older
than 75 was hampered by a survival effect. Importantly, the
increase in dementia or AD risk was not significant for
smokers under 65 [221]. This result is clearly different
from Parkinson’s disease, where smoking tendentially
caused more benefit than harm [222]. Why would this be?
The answer may lie in the special interaction of Ab with a7
nAChRs. Parri et al. [223] have recently reviewed this in
great detail. The fact that Ab binds to a7 nAChRs has been
observed and confirmed in numerous experimental settings,
including post-mortem AD brain; however, it is unclear if
this interaction results in inhibition or in stimulation of the
receptor, and whether this interaction is reversible by
agonists and antagonists. An intra-subunit allosteric bind-
ing pocket within the transmembrane domain of the a7
nAChR has been described as mechanism for non-com-
petitive antagonism by Ab (summarized by Parri et al.
[223]). A further complication with relevance to AD
pathology is the observation that cholinergic neurons in the
basal forebrain express a heteromeric a7b2 isoform [224,
225]. Liu et al. [224] have reported that the a7b2 receptor
is particularly sensitive to Ab, since concentrations as low
as 1 nM inhibited the functional responses to choline. They
furthermore noted that inhibition was strongest with Ab in
its oligomeric form, followed by fibrillar Ab, whereas
monomeric Ab was inactive. It is not clear why blockade
of the a7b2 receptor is neurotoxic to cholinergic neurons,
and if microglia cells from basal forebrain structures
express this heteromeric nicotinic receptor. Nevertheless,
one can begin to sketch a positive feedback process where
aging causes polarization of microglia towards a phenotype
that is less effective in phagocytosing and degrading Ab.
An overload of oligomeric Ab in the extracellular space
will block the a7b2 nicotinic receptor on basal forebrain
cholinergic neurons, and these die as a consequence. Less
acetylcholine leads to a reduction in a7 nAChR stimulation
of microglia cells, which results in further loss of their
phagocytic capacity. Diminished clearance of Ab ulti-
mately leads to extracellular precipitates, which
presumably are a further trigger to microglia recruitment,
inflammatory processes, and further toxicity to cholinergic
neurons (see Fig. 3). In this process, an early intervention
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with nicotine, cholinesterase inhibitors, and in principle, a7
nAChR agonists may delay the start of the vicious circle.
However, later in the process the availability of a7
nAChRs will be reduced by the negative interaction with
the accumulating oligomeric Ab. This would explain why
the toxic effects of smoking become dominant over the
neuroprotective effects in Alzheimer’s disease, but not (or
less) in Parkinson’s disease. If the above-sketched vicious
circle is correct, treatment with selective a7 nAChR ago-
nists would be useful as prophylaxis, but less so for
treatment of established severe AD-dementia.
Discussion
From a historical perspective, selective a7 nAChR agonists
have been targeted for cognitive deficits associated with
schizophrenia (for recent reviews see [151, 152, 226]) and
dementia in Alzheimer’s disease [227, 228]. Where
investigated, the dose–response relationships for the pro-
cognitive effects of a7 nAChR agonists usually display an
inverted U-shape, indicating that higher doses are less
effective than certain lower doses [142, 229–232].
Although the exact mechanism behind this profile remains
speculative, it has been frequently noted that high con-
centrations of agonist cause receptor desensitization and
suppression of functional responses [103, 233]. For
instance, in in vitro experiments in oocytes, high concen-
trations of a7 nAChR agonists desensitized the receptor
and blocked the calcium influx to the endogenous agonist
acetylcholine [234]. Similar inhibitory effects on calcium
influx were observed with synthetic a7 nAChR agonists at
high concentrations [235]. Remarkably though, at lower
concentrations a number of a7 nAChR agonists actually
may potentiate the acetylcholine-induced response [236].
Estimations of brain levels at which a7 nAChR agonists
evoke cognition-enhancing effects are in the range where
they potentiate the acetylcholine-induced calcium influx in
oocytes. It is therefore reasonable to assume that the pro-
cognitive effect of a7 nAChR agonists is due to an
enhancement of the acetylcholine-evoked response (known
as the ‘‘co-agonist hypothesis,’’ see [236, 237]). This
assumption is supported by preclinical data demonstrating
an additive pro-cognitive effect of donepezil and the a7
nAChR agonist encenicline [236]. Although not yet
reported, a similar co-agonist effect may occur at a7
receptors expressed by immune cells. If true, this would
imply that low doses of a a7 nAChR agonist would be
sufficient to enhance the anti-inflammatory response to the
endogenous agonists (choline and/or acetylcholine).
In reviews dealing with potential indications of
selective a7 nAChR agonists, the anti-inflammatory
activity has never taken central stage (at least up to


















Fig. 3 During aging the polarization of microglia gradually shifts
towards the M1 phenotype. Diminution of M2 polarization presum-
ably has negative consequences for Ab catabolism. When
extracellular Ab levels increase, several positive feedback loops are
triggered that ultimately lead to the demise of cholinergic neurons.
Activation of a7 nAChRs counteracts the loss of the M2 phenotype.
a7 nAChR agonists may furthermore compete with Ab at (mitochon-
drial?) nicotinic a7b2 receptors. Treatment with a7 nAChR agonists
might therefore delay the demise of cholinergic neurons, and thus
delay the onset of dementia
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in the pathophysiology of psychiatric disorders is, how-
ever, well recognized [130, 140, 167, 171, 176, 238]. In
the current review, we argue that several alternative
indications for a7 agonists may be delineated from their
effect on inflammation. Treatment with a7 nAChRs
agonist may result in inhibition of the pro-inflammatory
enzyme, GSK3b. In this respect, the treatment with a7-
agonists resembles lithium treatment. This similarity
may hold true not only for an indication like bipolar
disorder (improvement in both manic and depressive
symptoms) but also for suicide and neurological disor-
ders. Suicide is a major cause of death in depression,
bipolar disorder, and schizophrenia. Clinical data have
accumulated which indicate that inflammation and
microglia M1-polarization contribute to the pathophysi-
ology of suicide independent from the underlying
psychiatric disease [239–242]. Diverse pro-inflammatory
mechanisms such as autoimmunity, neurotropic patho-
gens, stress, or traumatic brain injury have been
documented in suicidal patients [243]. Since a7 nAChR
stimulation in immune cells can result in GSK3b inhi-
bition, and since the GSK3-inhibitor, lithium [244], is a
recognized anti-inflammatory [245] and anti-suicidal
compound [246, 247], one may propose the use of
nicotine a7-agonists for prevention of suicide. Chronic
treatment with lithium by virtue of its GSK3b inhibitory
effect also ameliorated the disease processes in preclin-
ical models of multiple sclerosis [248], Alzheimer [249–
251], and Parkinson’s disease [252–254]. It should be
noted though that GSK3b inhibition by lithium in these
models is just a symptomatic treatment and does not stop
the underlying pathological processes. Consequently,
once the pharmacotherapy is interrupted, the disease is
likely to return. Nevertheless, treatment with a a7
nAChR agonist might constitute a safe alternative to
lithium and one could propose the use of a7 nAChR
agonists for these neurological disorders.
In contrast to lithium treatment, the beneficial effect of
a7 nAChR stimulation is lost when the receptor is defec-
tive (or missing all together). An example was presented in
the autism section, and also in late-stage Alzheimer’s dis-
ease, the nicotine receptor owing to the interaction with the
b-amyloid protein may become severely dysfunctional.
One potential explanation for the lack of robust effects of
a7 nAChR agonists on cognitive function in schizophrenia
is the rapid desensitization of a7 nAChRs. This is a general
concern and applies to any a7 nAChR agonist indication. A
simple biomarker test for quantification of a7 nAChR
stimulation on an inflammation read-out would thus be
highly desirable. Perhaps the receptor desensitization of a7
nAChRs may be less of an issue for inflammation-related
indications. In this context, it is remarkable that basically
all a7 agonists were effective against negative symptoms
of schizophrenia (while effects on cognition were equivo-
cal). We would also expect that the beneficial effects of
smoking and cholinesterase-inhibitor-treatment would be
absent if a7 nAChRs would be desensitized for most of the
time. However, it must be admitted that a thorough
investigation of the concentration/response relationship for
the anti-inflammatory effect of any of the selective a7
nAChR agonists remains to be determined.
Since epidemiological data suggest that smoking exerts
a protective effect in Parkinson’s disease, a7 nAChR
agonists might be a preferable alternative to cholinesterase
inhibition and smoking. Registration studies for prophy-
lactic indications such as in Parkinson’s or Alzheimer’s
disease are however difficult, long lasting, and expensive,
and it is unlikely that companies will invest in these indi-
cations without the opportunity for registration in an acute
disorder. What could be the pioneer indication for a7
nAChR agonists? Based on clinical information from vagus
nerve stimulation treatment, depression would be a logical
choice. Unfortunately, depression studies generally suffer
from a high placebo response, making also the indication
‘depression’ less attractive.
We currently favor L-DOPA-induced dyskinesia as
possible ‘pioneer indication.’ It has been published that two
chemically distinct a7 nAChR agonists, ABT-107 and
AQW051, suppress L-DOPA-induced dyskinesias in
(MPTP-treated) Parkinsonian monkeys [255, 256]. The
precise mechanism by which this response is brought about
remains unknown; however, again it may involve GSK3
inhibition, since low-dose lithium was also recently shown
to be active in a similar Parkinson model in mice [254].
The beneficial effect of a7 nAChR agonists may involve
attenuation of MPTP-induced neuroinflammation and pro-
tection dopamine neurons in the substantia nigra pars
compacta [206]. Thus, efficacy for a7 nAChR agonists in
clinical trials of L-DOPA-induced dyskinesias could serve
as a clinical entry point to pave the way for indications
where longer treatment regimens are warranted.
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